17 completed, 4 active not recruiting, 3 not yet recruiting, 2 recruiting. 29 Phase 2, 5 Phase 1, 5 Phase 3.
Follow Atropine: new trials by email Literature Review of Atropine trials Research Report on Atropine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention 0.01% Atropine - Pre-myopia | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University Eye Hospital | 233 | 2026-03-30 | 2026-03-04 |
| Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center Atropine 0.05% Eye drops, Placebo ophthalmic solution - Myopia | Phase 2 / Phase 3 | Not yet recruiting | Mansoura University | 45 | 2025-09-01 | 2025-09-09 |
| The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group Atropine 0.01% eye drops - Focus on Axial Length | Phase 2 | Recruiting | Liaquat National Hospital & Medical College | 60 | 2025-07-13 | 2026-03-06 |
| A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control SHJ002, Atropine - Myopia, Progressive | Phase 2 | Active not recruiting | Sunhawk Vision Biotech, Inc. | 140 | 2025-01-22 | 2026-01-23 |
| Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade Sugammadex 1 mg/kg, Neostigmine + Atropine - Neuromuscular Blocking Agents, Reversal of Neuromuscular Blockade | Phase 1 / Phase 2 | Recruiting | Universitas Padjadjaran | 60 | 2024-11-05 | 2025-01-28 |
| Early Intervention for Premyopic Children MiyoSmart Spectacles, 0.01% atropine - Myopia, Preschool | Phase 2 | Active not recruiting | National Yang Ming Chiao Tung University Hospital | 240 | 2024-10-06 | 2025-06-12 |
| Role of Intralipid in Management of Organophosphorus Poisoning Intralipid, 20% Intravenous Emulsion, Intravenous Atropine Sulfate - Organophosphorus Poisoning | Phase 2 / Phase 3 | Withdrawn | Amani Hassan Abdel-Wahab | 2024-04-01 | 2025-10-03 | |
| Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation. Dexmedetomidine infusion, Dexmedetomidine bolus, Atropine Sulfate - Dexmedetomidine, Intubation Complication | Phase 2 | Completed | Kasr El Aini Hospital | 70 | 2024-04-01 | 2026-07-09 |
| Myopia Control: a Comparison Study Between Atropine and MiSight Atropine, MiSight contact lenses - Myopia | Phase 2 | Active not recruiting | Ann & Robert H Lurie Children's Hospital of Chicago | 348 | 2023-05-02 | 2026-07-22 |
| Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop CBT-009, Vehicle, Atropine Sulfate - Myopia, Progressive | Phase 1 / Phase 2 | Completed | Cloudbreak Therapeutics, LLC | 84 | 2022-07-20 | 2023-01-27 |
| Outcome of Moderate Severity in OPC Poisoning Patients When Treated With Pralidoxime Pralidoxime, Atropine - Organophosphorus Poisoning | Phase 2 | Completed | Sir Salimullah Medical College Mitford Hospital | 96 | 2022-06-01 | 2024-10-09 |
| The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS Scopolamine, atropine, edaravone and dexmedetomidine, Edaravone - Amyotrophic Lateral Sclerosis, Respiratory Function | Phase 2 | Unknown | Ruijin Hospital | 30 | 2020-11-01 | 2020-10-14 |
| Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade | Phase 2 | Completed | Seoul National University Hospital | 32 | 2020-04-29 | 2022-02-10 |
| Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade | Phase 2 | Completed | Seoul National University Hospital | 40 | 2019-08-12 | 2022-11-14 |
| Low-dose Atropine for the Prevention of Myopia Progression in Danish Children 0.1% atropine and 0.01% atropine, 0.01% atropine, 0.9% Sodium-chloride - Myopia | Phase 2 | Completed | Line Kessel | 97 | 2019-05-30 | 2025-06-29 |
| Low-dose Atropine Eye Drops to Reduce Progression of Myopia in Children in the United Kingdom Atropine Sulfate, Placebo - Myopia | Phase 2 | Active not recruiting | Belfast Health and Social Care Trust | 289 | 2019-04-03 | 2023-09-07 |
| Side Effects of Atropine (SEA) Study 0.01% concentration atropine drops - Myopia | Phase 1 / Phase 2 | Completed | Jeffrey J. Walline, OD PhD | 31 | 2018-07-23 | 2022-12-02 |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers E7 TCR cells, Aldesleukin, Fludarabine - Papillomavirus Infections, Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 224 | 2017-01-27 | 2026-03-09 |
| The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) Lidocaine, Sevoflurane, TIVA-TCI - Breast Cancer | Phase 2 | Completed | Iuliu Hatieganu University of Medicine and Pharmacy | 120 | 2016-08-01 | 2019-10-29 |
Showing 20 of 29. Sign in to see all of them.
Myopia (7) · Breast Neoplasms (2) · Myopia, Degenerative (2) · Organophosphate Poisoning (2) · Amyotrophic Lateral Sclerosis (1) · Bradycardia (1) · Carcinoma in Situ (1) · Heart Arrest (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Hypospadias (1) · Hypotension (1) · Pain (1) · Papillomavirus Infections (1) · Photophobia (1)
Assiut University (2) · Centre Hospitalier Intercommunal Creteil (2) · Seoul National University Hospital (2) · Amani Hassan Abdel-Wahab (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · Belfast Health and Social Care Trust (1) · Cloudbreak Therapeutics, LLC (1) · Isfahan University of Medical Sciences (1) · Iuliu Hatieganu University of Medicine and Pharmacy (1) · Jeffrey J. Walline, OD PhD (1) · Kasr El Aini Hospital (1) · Liaquat National Hospital & Medical College (1) · Line Kessel (1) · Magna Pharmaceuticals, Inc. (1) · Mansoura University (1)
United States (5) · Egypt (3) · France (2) · South Korea (2) · Taiwan (2) · Australia (1) · Austria (1) · Bangladesh (1) · China (1) · Denmark (1) · Indonesia (1) · Norway (1) · Pakistan (1) · Romania (1) · United Kingdom (1)
Augusto Azuara-Blanco, PhD FRCOphth (1) · Der-Chong Tsai, MD, PhD (1) · Hamdy A. Youssef, Professor (1) · Hee-Soo Kim, M.D, Ph.D. (1) · Hee-Soo Kim, M.D., Ph.D. (1) · Hina Nadeem, MBBS (1) · Jeffrey Walline (1) · Jun Liu, Professor (1) · Lars Wik, MD, PhD (1) · Magdalena Stec, OD (1) · Meryl Vedrenne-Cloquet, MD (1) · Michael Wolzt, MD (1) · Scott M Norberg, D.O. (1) · Stephen J Pollard, MD (1) · Tanya Revell, MD (1)
PMID 19934423, PMID 24247230, PMID 25794212, PMID 29715354, PMID 30881948, PMID 31653669, PMID 32616309, PMID 33301785, PMID 33558725, PMID 37124204, PMID 37904082, PMID 39422837, PMID 39522589, PMID 39739826, PMID 42276557
2017 (1), 2025 (1)